Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay

Research output: Contribution to journalArticle

Abstract

Objectives. To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7) in Brazil, Chile, and Uruguay. Methods. A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. Results. At the rate of diphtheria-tetanus-pertussis (DTP) vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs) yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil) to US$ 2 019 (Chile). At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333), making it cost effective and cost-saving. Conclusions. The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.

Original languageEnglish (US)
Pages (from-to)101-112
Number of pages12
JournalRevista Panamericana de Salud Publica/Pan American Journal of Public Health
Volume24
Issue number2
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Uruguay
Chile
Brazil
Vaccination
Economics
Costs and Cost Analysis
Vaccines
Quality-Adjusted Life Years
Diphtheria-Tetanus-Pertussis Vaccine
Conjugate Vaccines
Cost of Illness
Insurance Benefits
Health Care Costs
Demography
Parturition

Keywords

  • Brazil
  • Chile
  • Cost effectiveness
  • Pneumococcal vaccines
  • Streptococcus pneumoniae
  • Uruguay
  • Vaccination

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{0a2f7b8b73d44f39bd77a234a007f476,
title = "Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay",
abstract = "Objectives. To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7) in Brazil, Chile, and Uruguay. Methods. A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. Results. At the rate of diphtheria-tetanus-pertussis (DTP) vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs) yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil) to US$ 2 019 (Chile). At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333), making it cost effective and cost-saving. Conclusions. The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.",
keywords = "Brazil, Chile, Cost effectiveness, Pneumococcal vaccines, Streptococcus pneumoniae, Uruguay, Vaccination",
author = "Dagna Constenla",
year = "2008",
month = "8",
language = "English (US)",
volume = "24",
pages = "101--112",
journal = "Revista Panamericana de Salud Publica/Pan American Journal of Public Health",
issn = "1020-4989",
publisher = "Pan American Health Organization",
number = "2",

}

TY - JOUR

T1 - Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay

AU - Constenla, Dagna

PY - 2008/8

Y1 - 2008/8

N2 - Objectives. To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7) in Brazil, Chile, and Uruguay. Methods. A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. Results. At the rate of diphtheria-tetanus-pertussis (DTP) vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs) yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil) to US$ 2 019 (Chile). At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333), making it cost effective and cost-saving. Conclusions. The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.

AB - Objectives. To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7) in Brazil, Chile, and Uruguay. Methods. A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. Results. At the rate of diphtheria-tetanus-pertussis (DTP) vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs) yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil) to US$ 2 019 (Chile). At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333), making it cost effective and cost-saving. Conclusions. The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.

KW - Brazil

KW - Chile

KW - Cost effectiveness

KW - Pneumococcal vaccines

KW - Streptococcus pneumoniae

KW - Uruguay

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=54549127337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54549127337&partnerID=8YFLogxK

M3 - Article

C2 - 19062601

AN - SCOPUS:54549127337

VL - 24

SP - 101

EP - 112

JO - Revista Panamericana de Salud Publica/Pan American Journal of Public Health

JF - Revista Panamericana de Salud Publica/Pan American Journal of Public Health

SN - 1020-4989

IS - 2

ER -